MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (” MyMD” or “the Firm”), a professional stage pharmaceutical company devoted to prolonging healthy life expectancy, today revealed that the first person has actually been signed up in the Company’s Phase 2 clinical test of lead candidate MYMD-1, a dental immune regulator drug, as a therapy for postponing aging and broadening healthy lifespan.
The primary endpoint for the Stage 2 double-blind, placebo-controlled medical test is to accomplish a decrease in the distributing levels of (TNF-α), growth death factor receptor I (TNFRI) as well as IL-6. TNF-α as well as IL-6 are the healthy proteins in the body that trigger swelling as well as help turn on the procedure of aging. The second procedures of the test will be the security, tolerability, as well as pharmacokinetics in this population of individuals.
” In a Phase 1 clinical trial of MYMD-1, we demonstrated the drug’s statistically considerable efficacy in lowering levels of TNF-α, a principal in creating pathological aging, in the blood. The FDA has approved TNF-α decrease as the key endpoint for our Stage 2 study, which we believe settings us well for a successful Phase 2 end result,” claimed Chris Chapman, M.D., President, Supervisor as well as Principal Medical Police Officer of MyMD. “The initiation of client enrollment in this research study advances our goal to reduce the aging procedure, protect against loss of muscle cells in aging, limitation frailty, and extend healthy lifespan.”
MyMD has actually mentioned that there are no FDA-approved drugs for treating aging disorders and extending healthy and balanced lifespan people, a market anticipated to be at the very least $600 billion by 20251 according to a major investment financial institution. TNF-α blockers are one of the most prescribed drugs by income, a worldwide market of around $40 billion annually,2 as well as, according to Nature Aging journal,3 a downturn in aging that would certainly boost life expectancy by one year deserves $38 trillion as well as by one decade deserves $367 trillion.
Along with aging, MYMD-1’s distinctive activity in managing the body immune system as well as dealing with chronic swelling is being developed for the treatment of autoimmune condition, consisting of rheumatoid joint inflammation (RA), several sclerosis (MS), diabetes mellitus, and inflammatory bowel condition.
” We plan to begin writing procedures for a Phase 2 pilot study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman kept in mind. “The increasing occurrence of rheumatoid arthritis and other autoimmune and inflammatory conditions are driving need for TNF inhibitors like MYMD-1, and also our company believe our by mouth administered medication with really low poisoning would be disruptive to the $60 billion market for RA if authorized by the FDA for this sign.”
Rheumatoid joint inflammation impacts around 40 million people globally.4.
Originally developed for autoimmune diseases, MYMD-1’s main purpose is to slow down the aging procedure, stop sarcopenia and frailty, and also prolong healthy life-span. Because it can cross the blood-brain obstacle and gain access to the main nervous system (CNS), MYMD-1 is likewise positioned to be a possible therapy for brain-related problems. Its mechanism of action as well as efficiency in diseases consisting of multiple sclerosis (MS) and thyroiditis have actually been studied via cooperations with numerous academic establishments. MYMD-1 is additionally showing assurance in pre-clinical research studies as a potential therapy for article- COVID-19 issues and also as an anti-fibrotic and also anti-proliferation restorative.
MYMD-1 has shown effectiveness in pre-clinical studies in regulating the body immune system by performing as a selective inhibitor of lump necrosis factor-alpha (TNF-α), a motorist of chronic swelling. Unlike various other therapies, MYMD-1 has been shown in these pre-clinical studies to selectively obstruct TNF-α when it ends up being overactivated in autoimmune diseases and cytokine storms, however not obstruct it from doing its regular job of being a first responder to any kind of regular sort of moderate infection. MYMD-1’s convenience of oral application is another differentiator contrasted to presently readily available TNF-α blockers, all of which require shipment by injection or infusion. No accepted TNF inhibitor has actually ever been dosed orally. Additionally, the medication is not immunosuppressive and also has actually not been shown to create the serious negative effects typical with typical treatments that deal with inflammation.
Regarding MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a medical phase pharmaceutical company devoted to expanding healthy life expectancy, is focused on creating two unique therapeutic platforms that deal with the sources of condition instead of only addressing the symptoms. MYMD-1 is a medication system based on a scientific stage small molecule that manages the body immune system to control TNF-α, which drives persistent swelling, and also other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to postpone aging, increase durability, and deal with autoimmune diseases and also COVID-19- connected clinical depression. The Firm’s 2nd medication platform, Supera-CBD, is being created to treat persistent pain, dependency and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and also is being developed to resolve as well as improve upon the rapidly expanding CBD market, that includes both FDA accepted medicines as well as CBD items not presently managed as medications. To find out more, go to www.mymd.com.